Class information for:
Level 1: DIRECT ACTING ANTIVIRALS//SOFOSBUVIR//TELAPREVIR

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
1329 2715 38.4 79%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
7 4 INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY 1353914
99 3       HEPATITIS C VIRUS//HEPATITIS C//HEPATITIS B VIRUS 74452
26 2             HEPATITIS C VIRUS//HEPATITIS C//HCV 34145
1329 1                   DIRECT ACTING ANTIVIRALS//SOFOSBUVIR//TELAPREVIR 2715

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DIRECT ACTING ANTIVIRALS authKW 1908716 9% 70% 242
2 SOFOSBUVIR authKW 1514385 6% 77% 176
3 TELAPREVIR authKW 1339991 7% 59% 201
4 DACLATASVIR authKW 1258414 4% 92% 122
5 BOCEPREVIR authKW 1006308 5% 64% 140
6 SIMEPREVIR authKW 972979 4% 83% 104
7 NS5A INHIBITOR authKW 621328 2% 94% 59
8 LEDIPASVIR authKW 584227 2% 88% 59
9 TEXAS LIVER address 568742 2% 82% 62
10 DIRECT ACTING ANTIVIRAL AGENTS authKW 550967 3% 70% 70

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Gastroenterology & Hepatology 54661 43% 0% 1163
2 Infectious Diseases 9547 18% 0% 492
3 Virology 9434 15% 0% 394
4 Pharmacology & Pharmacy 3120 22% 0% 586
5 Microbiology 1344 11% 0% 287
6 Medicine, General & Internal 1225 11% 0% 306
7 Health Care Sciences & Services 647 4% 0% 101
8 Health Policy & Services 301 2% 0% 54
9 Immunology 159 6% 0% 152
10 Chemistry, Medicinal 139 3% 0% 79

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TEXAS LIVER 568742 2% 82% 62
2 BETTY GUY BEATTY INTEGRATED 154915 2% 33% 42
3 VIRAL HEPATITIS 96568 3% 10% 85
4 LIVER VIRGINIA 92835 1% 49% 17
5 REFERENCE VIRAL HEPATITIS B C D 75900 0% 75% 9
6 HOSP UNIV NANCY 69173 1% 31% 20
7 HLTH ECON PATIENT SAFETY 65422 0% 73% 8
8 HEPATOL 63447 7% 3% 184
9 LIVER DIS 57385 4% 5% 112
10 UNC LIVER 50087 0% 64% 7

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF VIRAL HEPATITIS 92691 5% 6% 135
2 LIVER INTERNATIONAL 45129 4% 4% 101
3 ANTIVIRAL THERAPY 26067 2% 4% 66
4 JOURNAL OF HEPATOLOGY 25727 5% 2% 132
5 HEPATOLOGY 19523 5% 1% 144
6 CLINICS IN LIVER DISEASE 9783 1% 4% 20
7 JOURNAL OF MEDICAL ECONOMICS 6927 0% 5% 12
8 EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY 6183 1% 3% 18
9 DIGESTIVE AND LIVER DISEASE 6083 1% 1% 38
10 CLINICAL INFECTIOUS DISEASES 4951 3% 1% 76

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 DIRECT ACTING ANTIVIRALS 1908716 9% 70% 242 Search DIRECT+ACTING+ANTIVIRALS Search DIRECT+ACTING+ANTIVIRALS
2 SOFOSBUVIR 1514385 6% 77% 176 Search SOFOSBUVIR Search SOFOSBUVIR
3 TELAPREVIR 1339991 7% 59% 201 Search TELAPREVIR Search TELAPREVIR
4 DACLATASVIR 1258414 4% 92% 122 Search DACLATASVIR Search DACLATASVIR
5 BOCEPREVIR 1006308 5% 64% 140 Search BOCEPREVIR Search BOCEPREVIR
6 SIMEPREVIR 972979 4% 83% 104 Search SIMEPREVIR Search SIMEPREVIR
7 NS5A INHIBITOR 621328 2% 94% 59 Search NS5A+INHIBITOR Search NS5A+INHIBITOR
8 LEDIPASVIR 584227 2% 88% 59 Search LEDIPASVIR Search LEDIPASVIR
9 DIRECT ACTING ANTIVIRAL AGENTS 550967 3% 70% 70 Search DIRECT+ACTING+ANTIVIRAL+AGENTS Search DIRECT+ACTING+ANTIVIRAL+AGENTS
10 ASUNAPREVIR 487059 2% 92% 47 Search ASUNAPREVIR Search ASUNAPREVIR

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 SARRAZIN, C , (2016) THE IMPORTANCE OF RESISTANCE TO DIRECT ANTIVIRAL DRUGS IN HCV INFECTION IN CLINICAL PRACTICE.JOURNAL OF HEPATOLOGY. VOL. 64. ISSUE 2. P. 486 -504 91 88% 46
2 BANERJEE, D , REDDY, KR , (2016) REVIEW ARTICLE: SAFETY AND TOLERABILITY OF DIRECT-ACTING ANTI-VIRAL AGENTS IN THE NEW ERA OF HEPATITIS C THERAPY.ALIMENTARY PHARMACOLOGY & THERAPEUTICS. VOL. 43. ISSUE 6. P. 674 -696 65 71% 13
3 ESPOSITO, I , TRINKS, J , SORIANO, V , (2016) HEPATITIS C VIRUS RESISTANCE TO THE NEW DIRECT-ACTING ANTIVIRALS.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 12. ISSUE 10. P. 1197 -1209 77 91% 1
4 MAJUMDAR, A , KITSON, MT , ROBERTS, SK , (2016) SYSTEMATIC REVIEW: CURRENT CONCEPTS AND CHALLENGES FOR THE DIRECT-ACTING ANTIVIRAL ERA IN HEPATITIS C CIRRHOSIS.ALIMENTARY PHARMACOLOGY & THERAPEUTICS. VOL. 43. ISSUE 12. P. 1276 -1292 60 72% 12
5 CUYPERS, L , CECCHERINI-SILBERSTEIN, F , VAN LAETHEM, K , LI, GD , VANDAMME, AM , ROCKSTROH, JK , (2016) IMPACT OF HCV GENOTYPE ON TREATMENT REGIMENS AND DRUG RESISTANCE: A SNAPSHOT IN TIME.REVIEWS IN MEDICAL VIROLOGY. VOL. 26. ISSUE 6. P. 408 -434 87 78% 0
6 LONTOK, E , HARRINGTON, P , HOWE, A , KIEFFER, T , LENNERSTRAND, J , LENZ, O , MCPHEE, F , MO, HM , PARKIN, N , PILOT-MATIAS, T , ET AL (2015) HEPATITIS C VIRUS DRUG RESISTANCE-ASSOCIATED SUBSTITUTIONS: STATE OF THE ART SUMMARY.HEPATOLOGY. VOL. 62. ISSUE 5. P. 1623 -1632 44 90% 47
7 CENTO, V , CHEVALIEZ, S , PERNO, CF , (2015) RESISTANCE TO DIRECT-ACTING ANTIVIRAL AGENTS: CLINICAL UTILITY AND SIGNIFICANCE.CURRENT OPINION IN HIV AND AIDS. VOL. 10. ISSUE 5. P. 381 -389 64 93% 6
8 DE CLERCQ, E , (2015) DEVELOPMENT OF ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C AT AN ACCELERATING PACE.REVIEWS IN MEDICAL VIROLOGY. VOL. 25. ISSUE 4. P. 254 -267 86 68% 3
9 ENOMOTO, M , KAWADA, N , TAMORI, A , (2016) RECENT ADVANCES IN ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C.MEDIATORS OF INFLAMMATION. VOL. . ISSUE . P. - 59 79% 4
10 STAHMEYER, JT , ROSSOL, S , KRAUTH, C , (2015) OUTCOMES, COSTS AND COST-EFFECTIVENESS OF TREATING HEPATITIS C WITH DIRECT ACTING ANTIVIRALS.JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH. VOL. 4. ISSUE 3. P. 267 -277 57 97% 2

Classes with closest relation at Level 1


Rank Class id link
1 1075 RIBAVIRIN//IL28B//INTERLEUKIN 28B
2 4553 NS5B POLYMERASE//NS5B//HCV NS5B POLYMERASE
3 21543 ACUTE HEPATITIS C//ACUTE HEPATITIS C VIRUS//ACUTE HCV
4 4541 HEPATITIS C//HEPATITIS C TREATMENT//JENS
5 6218 HCV GENOTYPES//HEPATITIS C VIRUS//HCV GENOTYPING
6 29687 HCV CORE ANTIGEN//HEPATITIS C VIRUS CORE ANTIGEN//HCV CORE ANTIGEN ASSAY
7 7212 HEPATITIS C RECURRENCE//RECURRENT HEPATITIS C//LIVER TRANSPLANTATION
8 835 HEPATITIS C VIRUS//STUDY HEPATITIS C//VIROL 2
9 3304 CO INFECTION//HIV HCV COINFECTION//HIV
10 2382 CHRONIC HEPATITIS C//RIBAVIRIN//INTERFERON

Go to start page